Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

doi:10.1016/S1474-4422(18)30460-5

Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

Publikation: Bidrag til tidsskrift › Review › peer review

Abstract

Spinal cord involvement is an important cause of disability in patients with multiple sclerosis or neuromyelitis optica spectrum disorders (NMOSDs). Multiple sclerosis and NMOSDs can be distinguished from other disorders that cause myelopathy by results from laboratory and radiological investigations. However, limitations in the sensitivity and specificity of spinal cord imaging and poor correlation with disability megasures have impeded the understanding of the relationship between spinal cord involvement and clinical manifestations. Nevertheless, studies of the pathological features of multiple sclerosis and NMOSDs have shown that quantitatively different mechanisms lead to differences in clinical course and pattern of accrual of permanent disability in the two disorders. Better understanding of these mechanisms is necessary to develop more informative clinical measures, electrophysiological methods, fluid biomarkers, and imaging techniques to detect and monitor spinal cord involvement in the diagnosis and management of patients with multiple sclerosis or NMOSDs, and as outcome measures in clinical trials.

Originalsprog	Engelsk
Tidsskrift	The Lancet Neurology
Vol/bind	18
Udgave nummer	2
Sider (fra-til)	185-197
Antal sider	13
ISSN	1474-4422
DOI	https://doi.org/10.1016/S1474-4422(18)30460-5
Status	Udgivet - 2019

Finansiering

OC reports grants from the MS Society of Great Britain & Northern Ireland, National Institute for Health Research University College London Hospital Biomedical Research Centre (NIHR UCLH BRC), National Multiple Sclerosis Society, NIHR, the Spinal Cord Research Foundation, Rosetrees Trust, Progressive MS Alliance, Bioclinica & GE Neuro, and EU-H2020; has received consultancy fees from Novartis, Teva Pharmaceutical Industries, Roche, Biogen, and Merck; personal fees and other payments from Neurology ; and non-financial and other support from the Multiple Sclerosis Journal . JAC reports consultancy fees from Adamas Pharmaceuticals, Celgene, Convelo, EMD Serono, Novartis, and PendoPharm; and speaking fees from Mylan and Synthon. SCR reports personal fees from the National Multiple Sclerosis Society, European Committee for Treatment and Research in Multiple Sclerosis, Ionis Pharmaceuticals, Opexa Therapeutics, Teva Pharmaceutical Industries, and TG Therapeutics; personal fees and other payments from F Hoffmann-LaRoche, Medday Pharmaceuticals SA, MedImmune Inc, Merck Serono, Novartis, and Observatoire Français pour la Sclérosis en Plaques; and non-financial support from Scientific and Clinical Review Associates LLC. BGW reports personal fees from Novartis, MedImmune, Alexion, Caladrius Biosciences, Biogen-Idec, Roivant, and Brainstorm Therapeutics; has a patent of NMO-IgG for diagnosis of neuromyelitis optica with royalties paid to RSR Ltd, Oxford University, Hospices Civil de Lyon, and MVZ Labor PD Dr Volkmann und Kollegen GbR. This Review was motivated by the International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders held on May 18–20, 2017 in Berlin, Germany. The Conference was convened under the auspices of the International Advisory Committee on Clinical Trials in Multiple Sclerosis. Both the Committee and the Conference were sponsored and supported by the US National Multiple Sclerosis Society and the European Committee for Treatment and Research in Multiple Sclerosis. All Conference participants ( appendix ) were provided with the opportunity to review a draft of the manuscript and suggest revisions before finalisation. There was no involvement of the sponsors in the design of the Conference, or in the collection, analysis, or interpretation of data involved in the publication, nor in the writing of the manuscript, nor the decision to submit it for publication. We thank Alex Róvira (Unidad de Resonancia Magnética, Hospital Universitari Vall d'Hebron, Barcelona, Spain) for providing figure 1 , Eoin Flanagan (Department of Neurology, Mayo Clinic, Rochester, MN, USA) for providing figure 3 , and Claudia Lucchinetti (Department of Neurology, Mayo Clinic, Rochester, MN, USA) for providing figure 4 .

Adgang til dokumentet

10.1016/S1474-4422(18)30460-5

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

@article{d6439b0084f74d07bdb567b87ada22df,

title = "Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders",

abstract = "Spinal cord involvement is an important cause of disability in patients with multiple sclerosis or neuromyelitis optica spectrum disorders (NMOSDs). Multiple sclerosis and NMOSDs can be distinguished from other disorders that cause myelopathy by results from laboratory and radiological investigations. However, limitations in the sensitivity and specificity of spinal cord imaging and poor correlation with disability megasures have impeded the understanding of the relationship between spinal cord involvement and clinical manifestations. Nevertheless, studies of the pathological features of multiple sclerosis and NMOSDs have shown that quantitatively different mechanisms lead to differences in clinical course and pattern of accrual of permanent disability in the two disorders. Better understanding of these mechanisms is necessary to develop more informative clinical measures, electrophysiological methods, fluid biomarkers, and imaging techniques to detect and monitor spinal cord involvement in the diagnosis and management of patients with multiple sclerosis or NMOSDs, and as outcome measures in clinical trials.",

author = "Olga Ciccarelli and Jeffrey Cohen and Stephen Reingold and Weinshenker, \{Brian G.\} and Amato, \{Maria Pia\} and Brenda Banwell and Frederik Barkhof and Bruce Bebo and Burkhard Becher and Fran{\c c}ois Bethoux and Alexander Brandt and Wallace Brownlee and Peter Calabresi and Jeremy Chatway and Claudia Chien and Tanuja Chitnis and Jeffrey Cohen and Giancarlo Comi and Jorge Correale and \{De S{\`e}ze\}, Jerome and \{De Stefano\}, Nicola and Franz Fazekas and Eoin Flanagan and Mark Freedman and Kazuo Fujihara and Steven Galetta and Myla Goldman and Benjamin Greenberg and Hartung, \{Hans Peter\} and Bernhard Hemmer and Anke Henning and Izlem Izbudak and Ludwig Kappos and Hans Lassmann and Cornelia Laule and Michael Levy and Fred Lublin and Claudia Lucchinetti and Carsten Lukas and Marrie, \{Ruth Ann\} and Aaron Miller and David Miller and Xavier Montalban and Ellen Mowry and Sebastien Ourselin and Friedemann Paul and Daniel Pelletier and Ranjeva, \{Jean Philippe\} and Daniel Reich and \{Soelberg Sorensen\}, Per and \{International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders\}",

year = "2019",

doi = "10.1016/S1474-4422(18)30460-5",

language = "English",

volume = "18",

pages = "185--197",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

AU - Ciccarelli, Olga

AU - Cohen, Jeffrey

AU - Reingold, Stephen

AU - Weinshenker, Brian G.

AU - Amato, Maria Pia

AU - Banwell, Brenda

AU - Barkhof, Frederik

AU - Bebo, Bruce

AU - Becher, Burkhard

AU - Bethoux, François

AU - Brandt, Alexander

AU - Brownlee, Wallace

AU - Calabresi, Peter

AU - Chatway, Jeremy

AU - Chien, Claudia

AU - Chitnis, Tanuja

AU - Cohen, Jeffrey

AU - Comi, Giancarlo

AU - Correale, Jorge

AU - De Sèze, Jerome

AU - De Stefano, Nicola

AU - Fazekas, Franz

AU - Flanagan, Eoin

AU - Freedman, Mark

AU - Fujihara, Kazuo

AU - Galetta, Steven

AU - Goldman, Myla

AU - Greenberg, Benjamin

AU - Hartung, Hans Peter

AU - Hemmer, Bernhard

AU - Henning, Anke

AU - Izbudak, Izlem

AU - Kappos, Ludwig

AU - Lassmann, Hans

AU - Laule, Cornelia

AU - Levy, Michael

AU - Lublin, Fred

AU - Lucchinetti, Claudia

AU - Lukas, Carsten

AU - Marrie, Ruth Ann

AU - Miller, Aaron

AU - Miller, David

AU - Montalban, Xavier

AU - Mowry, Ellen

AU - Ourselin, Sebastien

AU - Paul, Friedemann

AU - Pelletier, Daniel

AU - Ranjeva, Jean Philippe

AU - Reich, Daniel

AU - Soelberg Sorensen, Per

AU - International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

PY - 2019

Y1 - 2019

N2 - Spinal cord involvement is an important cause of disability in patients with multiple sclerosis or neuromyelitis optica spectrum disorders (NMOSDs). Multiple sclerosis and NMOSDs can be distinguished from other disorders that cause myelopathy by results from laboratory and radiological investigations. However, limitations in the sensitivity and specificity of spinal cord imaging and poor correlation with disability megasures have impeded the understanding of the relationship between spinal cord involvement and clinical manifestations. Nevertheless, studies of the pathological features of multiple sclerosis and NMOSDs have shown that quantitatively different mechanisms lead to differences in clinical course and pattern of accrual of permanent disability in the two disorders. Better understanding of these mechanisms is necessary to develop more informative clinical measures, electrophysiological methods, fluid biomarkers, and imaging techniques to detect and monitor spinal cord involvement in the diagnosis and management of patients with multiple sclerosis or NMOSDs, and as outcome measures in clinical trials.

AB - Spinal cord involvement is an important cause of disability in patients with multiple sclerosis or neuromyelitis optica spectrum disorders (NMOSDs). Multiple sclerosis and NMOSDs can be distinguished from other disorders that cause myelopathy by results from laboratory and radiological investigations. However, limitations in the sensitivity and specificity of spinal cord imaging and poor correlation with disability megasures have impeded the understanding of the relationship between spinal cord involvement and clinical manifestations. Nevertheless, studies of the pathological features of multiple sclerosis and NMOSDs have shown that quantitatively different mechanisms lead to differences in clinical course and pattern of accrual of permanent disability in the two disorders. Better understanding of these mechanisms is necessary to develop more informative clinical measures, electrophysiological methods, fluid biomarkers, and imaging techniques to detect and monitor spinal cord involvement in the diagnosis and management of patients with multiple sclerosis or NMOSDs, and as outcome measures in clinical trials.

U2 - 10.1016/S1474-4422(18)30460-5

DO - 10.1016/S1474-4422(18)30460-5

M3 - Review

C2 - 30663608

AN - SCOPUS:85060049167

SN - 1474-4422

VL - 18

SP - 185

EP - 197

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 2

ER -